Novartis Ag Stock Book Value Per Share
NVSEF Stock | USD 96.00 0.89 0.94% |
Novartis AG fundamentals help investors to digest information that contributes to Novartis' financial success or failures. It also enables traders to predict the movement of Novartis Pink Sheet. The fundamental analysis module provides a way to measure Novartis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novartis pink sheet.
Novartis |
Novartis AG Company Book Value Per Share Analysis
Novartis' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Novartis Book Value Per Share | 28.00 X |
Most of Novartis' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novartis AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Competition |
In accordance with the recently published financial statements, the book value per share of Novartis AG is about 27.997 times. This is 1746.88% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The book value per share for all United States stocks is 98.55% higher than that of the company.
Novartis Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novartis' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics of similar companies.Novartis is currently under evaluation in book value per share category among related companies.
Novartis Fundamentals
Return On Equity | 0.11 | |||
Return On Asset | 0.0645 | |||
Profit Margin | 0.13 % | |||
Operating Margin | 0.25 % | |||
Current Valuation | 207.39 B | |||
Shares Outstanding | 2.12 B | |||
Shares Owned By Insiders | 3.74 % | |||
Shares Owned By Institutions | 33.74 % | |||
Price To Earning | 25.00 X | |||
Price To Book | 3.22 X | |||
Price To Sales | 3.82 X | |||
Revenue | 51.83 B | |||
Gross Profit | 36.74 B | |||
EBITDA | 16.39 B | |||
Net Income | 6.96 B | |||
Cash And Equivalents | 19.1 B | |||
Cash Per Share | 8.81 X | |||
Total Debt | 20.24 B | |||
Debt To Equity | 0.47 % | |||
Current Ratio | 1.31 X | |||
Book Value Per Share | 28.00 X | |||
Cash Flow From Operations | 14.24 B | |||
Earnings Per Share | 3.17 X | |||
Price To Earnings To Growth | 5.67 X | |||
Number Of Employees | 102 K | |||
Beta | 0.47 | |||
Market Capitalization | 183.29 B | |||
Total Asset | 117.45 B | |||
Working Capital | 1.28 B | |||
Current Asset | 25.88 B | |||
Current Liabilities | 24.6 B | |||
Z Score | 5.4 | |||
Annual Yield | 0.04 % | |||
Five Year Return | 3.29 % | |||
Net Asset | 117.45 B | |||
Last Dividend Paid | 3.46 |
About Novartis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novartis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novartis' short interest history, or implied volatility extrapolated from Novartis options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Novartis AG information on this page should be used as a complementary analysis to other Novartis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Novartis Pink Sheet analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
CEOs Directory Screen CEOs from public companies around the world | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |